who is not a candidate for glp 1 Should Take GLP-1 Medication? Clinical Contraindications – PlexusDx Considering GLP-1s: A Guide to

BPC 157 also acts as a free radical scavenger, counteracts free radical-induced lesions, and normalizes NO and MDA levels in tissues and during ischemia and reperfusion

PHQ-9, Patient Health Questionnaire 9

JAK inhibitors (tofacitinib, upadacitinib) and the S1P receptor modulator ozanimod are also approved for use in appropriate patients with moderate-to-severe UC when conventional therapy or biologics are not suitable or have failed

Dose escalation (titration): Gradually increasing your dose over several weeks to reduce side effects

Additionally, Kazanjian suggested embracing a healthy lifestyle as a part of your prevention plan